These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 11401142

  • 1. Cessation of platelet-mediated cyclic canine coronary occlusion after thrombolysis by combining nitric oxide inhalation with phosphodiesterase-5 inhibition.
    Schmidt U, Han RO, DiSalvo TG, Guerrero JL, Gold HK, Zapol WM, Bloch KD, Semigran MJ.
    J Am Coll Cardiol; 2001 Jun 01; 37(7):1981-8. PubMed ID: 11401142
    [Abstract] [Full Text] [Related]

  • 2. Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis.
    Lewis GD, Witzke C, Colon-Hernandez P, Guerrero JL, Bloch KD, Semigran MJ.
    J Am Coll Cardiol; 2006 Apr 04; 47(7):1471-7. PubMed ID: 16580539
    [Abstract] [Full Text] [Related]

  • 3. Inhaled nitric oxide increases coronary artery patency after thrombolysis.
    Adrie C, Bloch KD, Moreno PR, Hurford WE, Guerrero JL, Holt R, Zapol WM, Gold HK, Semigran MJ.
    Circulation; 1996 Oct 15; 94(8):1919-26. PubMed ID: 8873669
    [Abstract] [Full Text] [Related]

  • 4. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K, Kloner RA.
    Cardiovasc Res; 1993 Jun 15; 27(6):925-34. PubMed ID: 8221780
    [Abstract] [Full Text] [Related]

  • 5. Effects of intravenous Zaprinast and inhaled nitric oxide on pulmonary hemodynamics and gas exchange in an ovine model of acute respiratory distress syndrome.
    Adrie C, Holzmann A, Hirani WM, Zapol WM, Hurford WE.
    Anesthesiology; 2000 Aug 15; 93(2):422-30. PubMed ID: 10910492
    [Abstract] [Full Text] [Related]

  • 6. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
    Nicolini FA, Nichols WW, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1991 Apr 15; 25(4):283-9. PubMed ID: 1909212
    [Abstract] [Full Text] [Related]

  • 7. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR, Lynch JJ, Sitko GR, Mellott MJ, Holahan MA, Stabilito II, Stranieri MT, Zhang G, Lynch RJ, Manno PD.
    J Pharmacol Exp Ther; 1993 Sep 15; 266(3):1501-11. PubMed ID: 8371153
    [Abstract] [Full Text] [Related]

  • 8. Site-specific effect of guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition in isolated lamb lungs.
    Steinhorn RH, Gordon JB, Tod ML.
    Crit Care Med; 2000 Feb 15; 28(2):490-5. PubMed ID: 10708189
    [Abstract] [Full Text] [Related]

  • 9. Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease.
    Ivy DD, Kinsella JP, Ziegler JW, Abman SH.
    J Thorac Cardiovasc Surg; 1998 Apr 15; 115(4):875-82. PubMed ID: 9576224
    [Abstract] [Full Text] [Related]

  • 10. Combined therapy with zaprinast and inhaled nitric oxide abolishes hypoxic pulmonary hypertension.
    Nagamine J, Hill LL, Pearl RG.
    Crit Care Med; 2000 Jul 15; 28(7):2420-4. PubMed ID: 10921573
    [Abstract] [Full Text] [Related]

  • 11. Effects of MDL 28,133A, a 5-HT2 receptor antagonist, on platelet aggregation and coronary thrombosis in dogs.
    Hsieh CP, Sakai K, Bruns GC, Dage RC.
    J Cardiovasc Pharmacol; 1994 Nov 15; 24(5):761-72. PubMed ID: 7532754
    [Abstract] [Full Text] [Related]

  • 12. Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension.
    Ziegler JW, Ivy DD, Wiggins JW, Kinsella JP, Clarke WR, Abman SH.
    Am J Respir Crit Care Med; 1998 Nov 15; 158(5 Pt 1):1388-95. PubMed ID: 9817684
    [Abstract] [Full Text] [Related]

  • 13. Antithrombotic activity of the phosphodiesterase III inhibitor pelrinone in a canine model of coronary artery thrombosis: enhancement of efficacy with concurrent alpha 2-adrenergic antagonism.
    Kitzen JM, McCallum JD, Harvey C, Morin ME.
    J Cardiovasc Pharmacol; 1991 Dec 15; 18(6):777-90. PubMed ID: 1725888
    [Abstract] [Full Text] [Related]

  • 14. Combined administration of intravenous dipyridamole and inhaled nitric oxide to assess reversibility of pulmonary arterial hypertension in potential cardiac transplant recipients.
    Lepore JJ, Dec GW, Zapol WM, Bloch KD, Semigran MJ.
    J Heart Lung Transplant; 2005 Nov 15; 24(11):1950-6. PubMed ID: 16297803
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of arterial thrombus formation in two canine models: comparison of ancrod, a fibrinogen-depleting agent, the thrombin-inhibitor r-hirudin, and the glycoprotein 11b/IIIa-receptor antagonist Ro 43-8857.
    Rübsamen K, Hornberger W, Kirchengast M.
    Thromb Haemost; 1995 Nov 15; 74(5):1353-60. PubMed ID: 8607122
    [Abstract] [Full Text] [Related]

  • 16. The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide.
    Thusu KG, Morin FC, Russell JA, Steinhorn RH.
    Am J Respir Crit Care Med; 1995 Nov 15; 152(5 Pt 1):1605-10. PubMed ID: 7582302
    [Abstract] [Full Text] [Related]

  • 17. Effect of aspirin and epinephrine on experimentally induced thrombogenesis in dogs. A parallelism between in vivo and ex vivo thrombosis models.
    Roux SP, Sakariassen KS, Turitto VT, Baumgartner HR.
    Arterioscler Thromb; 1991 Nov 15; 11(5):1182-91. PubMed ID: 1911705
    [Abstract] [Full Text] [Related]

  • 18. Intravenous dipyridamole enhances the effects of inhaled nitric oxide and prevents rebound pulmonary hypertension in piglets.
    Foubert L, De Wolf D, Mareels K, Van Belleghem Y, Reyntjens K, Mortier E, Van Nooten G.
    Pediatr Res; 2002 Nov 15; 52(5):730-6. PubMed ID: 12409521
    [Abstract] [Full Text] [Related]

  • 19. Selective pulmonary vasodilation induced by aerosolized zaprinast.
    Ichinose F, Adrie C, Hurford WE, Bloch KD, Zapol WM.
    Anesthesiology; 1998 Feb 15; 88(2):410-6. PubMed ID: 9477062
    [Abstract] [Full Text] [Related]

  • 20. Pulmonary and systemic effects of the phosphodiesterase inhibitor dipyridamole in newborn lambs with persistent pulmonary hypertension.
    Dukarm RC, Morin FC, Russell JA, Steinhorn RH.
    Pediatr Res; 1998 Dec 15; 44(6):831-7. PubMed ID: 9853914
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.